Interventional Cardiology
CTO intervention techniques and outcomes
Also called CTO PCI, chronic total occlusion, CTO intervention
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
“CHIP-BCIS3 is vital and should end the “routine” elective Impella use in HRPCI. But, I’d against reading it as a verdict on selective use. In my experience (non-surgical candidates, very high-risk anatomy), outcomes have looked different, and I suspect technique matters: the…”
Expert labels are toward CHIP-BCIS3's result, from named public quotes (n=2). As of Nov 13, 2026.
Unverified · drafted by AI from the sources cited below
Coronary occlusion is defined as a complete blockage of blood flow through one of the coronary arteries, which is usually from coronary atherosclerosis.1 Percutaneous coronary intervention is a family of percutaneous techniques that are used to manage coronary occlusion.2
Percutaneous coronary intervention encompasses techniques used to manage coronary occlusion, including standard balloon angioplasty, the placement of intracoronary stents, and atheroablative technologies.1 Intravascular imaging-guided percutaneous coronary intervention with intravascular ultrasound or optical coherence tomography showed superior clinical outcomes compared with angiography-guided percutaneous coronary intervention.2 Additionally, in a trial of 1500 patients with three-vessel coronary artery disease, fractional flow reserve-guided percutaneous coronary intervention was compared with coronary-artery bypass grafting.3
The prognostic value of Selvester QRS scoring in patients with coronary chronic total occlusion
Journal of Electrocardiology — Xu T — Nov 2026
Association of ALI and mCONUT With In‐Hospital De Novo Heart Failure in Patients With STEMI
Clinical Cardiology — Dai Z — Nov 2026
CCU #bruinhearts Journal Club OPTIMAL
UCLA #bruinhearts — Tue, Sep 22, 3:00 PM EDT — 1 attended
ORBITA-CTO: The Heart of the Matter
OPCI Journal Club — Fri, Jun 26, 5:49 PM EDT — 15 attended
Sessions from public communities on Synapse. RSVP to join the live discussion.
Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial
The Lancet
443 citations · 2021 · among the most cited on Chronic total occlusion PCI
Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery
New England Journal of Medicine — Fearon W
375 citations · 2021 · among the most cited on Chronic total occlusion PCI
Optical Coherence Tomography–Guided or Intravascular Ultrasound–Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial
Circulation — Kang D
176 citations · 2023 · among the most cited on Chronic total occlusion PCI
Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial
The Lancet — Ge Z
167 citations · 2024 · among the most cited on Chronic total occlusion PCI
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Gill K — Oct 2026
Across this topic’s most recent indexed papers.
“ORBITA-CTO confirms that CTO PCI reduces angina frequency beyond placebo at 24 weeks, supporting more selective rather than broad procedural use.”
“The OPTIMAL trial demonstrated no significant clinical benefit for routine IVUS guidance over angiography alone in unprotected left main coronary disease.”
Brigham and Women's Hospital
h-index 255 · 264k citations
Cardiovascular risk, evaluation and management in patients with hypertriglyceridaemia: a Consensus Statement from the International Atherosclerosis Society
Brigham and Women's Hospital
h-index 249 · 299k citations
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial
Yale New Haven Hospital
h-index 227 · 229k citations
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation
Mount Sinai Hospital
h-index 223 · 265k citations
Basic Biology of Oxidative Stress and the Cardiovascular System
Leiden University
h-index 219 · 432k citations
Prevalence and Prognostic Implications of Discordant Grading and Flow-Gradient Patterns in Moderate Aortic Stenosis
The University of Melbourne
h-index 215 · 244k citations
Angiography-derived physiology versus alternative strategies for guiding coronary revascularization: Protocol for a systematic review and meta-analysis
Most-cited researchers publishing on Chronic total occlusion PCI.
